Emergency thrombolysis in acute myocardial infarction

Magda Heras, James H. Chesebro, Bernard G. Gersh, David Holmes, Michael B. Mock, Valentin Fuster

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The goal of thrombolytic treatment in acute myocardial infarction is to reestablish permanent blood flow, salvage ischemic myocardium, and reduce mortality. If patency is achieved sufficiently early and is maintained, left ventricular function is preserved and mortality decreases. The recent experience with tissue plasminogen activator and streptokinase in the TIMI I trial is reviewed with specific attention to reperfusion, reocclusion, and bleeding. Other studies concerning left ventricular preservation and mortality are also discussed. Current guidelines for antithrombotic therapy and thrombolysis are discussed. It is extremely important to adequately select patients to avoid side effects. Thorough lysis of the thrombus must be achieved to reduce the risk of rethrombosis. Simultaneous heparin should be administered to treat ongoing thrombosis. Additional antithrombotic therapy with aspirin and acute vasodilation to reduce vasoconstriction probably also decrease the likelihood of reocclusion. Because this treatment predisposes to bleeding, extreme care should be taken to avoid vascular punctures and invasive procedures in these patients. The association of immediate percutaneous transluminal coronary angioplasty has not been beneficial in preventing further events; on the contrary, adverse effects have been associated with this acute intervention.

Original languageEnglish (US)
Pages (from-to)1168-1175
Number of pages8
JournalAnnals of emergency medicine
Volume17
Issue number11
DOIs
StatePublished - Jan 1 1988

Fingerprint

Emergencies
Myocardial Infarction
Mortality
Thrombosis
Hemorrhage
Streptokinase
Coronary Balloon Angioplasty
Tissue Plasminogen Activator
Therapeutics
Vasoconstriction
Left Ventricular Function
Punctures
Vasodilation
Aspirin
Reperfusion
Blood Vessels
Heparin
Myocardium
Guidelines

Keywords

  • myocardial infarction
  • thrombolysis

ASJC Scopus subject areas

  • Emergency Medicine

Cite this

Heras, M., Chesebro, J. H., Gersh, B. G., Holmes, D., Mock, M. B., & Fuster, V. (1988). Emergency thrombolysis in acute myocardial infarction. Annals of emergency medicine, 17(11), 1168-1175. https://doi.org/10.1016/S0196-0644(88)80063-5

Emergency thrombolysis in acute myocardial infarction. / Heras, Magda; Chesebro, James H.; Gersh, Bernard G.; Holmes, David; Mock, Michael B.; Fuster, Valentin.

In: Annals of emergency medicine, Vol. 17, No. 11, 01.01.1988, p. 1168-1175.

Research output: Contribution to journalArticle

Heras, M, Chesebro, JH, Gersh, BG, Holmes, D, Mock, MB & Fuster, V 1988, 'Emergency thrombolysis in acute myocardial infarction', Annals of emergency medicine, vol. 17, no. 11, pp. 1168-1175. https://doi.org/10.1016/S0196-0644(88)80063-5
Heras, Magda ; Chesebro, James H. ; Gersh, Bernard G. ; Holmes, David ; Mock, Michael B. ; Fuster, Valentin. / Emergency thrombolysis in acute myocardial infarction. In: Annals of emergency medicine. 1988 ; Vol. 17, No. 11. pp. 1168-1175.
@article{204c38bc50714bbaadac076d910d6288,
title = "Emergency thrombolysis in acute myocardial infarction",
abstract = "The goal of thrombolytic treatment in acute myocardial infarction is to reestablish permanent blood flow, salvage ischemic myocardium, and reduce mortality. If patency is achieved sufficiently early and is maintained, left ventricular function is preserved and mortality decreases. The recent experience with tissue plasminogen activator and streptokinase in the TIMI I trial is reviewed with specific attention to reperfusion, reocclusion, and bleeding. Other studies concerning left ventricular preservation and mortality are also discussed. Current guidelines for antithrombotic therapy and thrombolysis are discussed. It is extremely important to adequately select patients to avoid side effects. Thorough lysis of the thrombus must be achieved to reduce the risk of rethrombosis. Simultaneous heparin should be administered to treat ongoing thrombosis. Additional antithrombotic therapy with aspirin and acute vasodilation to reduce vasoconstriction probably also decrease the likelihood of reocclusion. Because this treatment predisposes to bleeding, extreme care should be taken to avoid vascular punctures and invasive procedures in these patients. The association of immediate percutaneous transluminal coronary angioplasty has not been beneficial in preventing further events; on the contrary, adverse effects have been associated with this acute intervention.",
keywords = "myocardial infarction, thrombolysis",
author = "Magda Heras and Chesebro, {James H.} and Gersh, {Bernard G.} and David Holmes and Mock, {Michael B.} and Valentin Fuster",
year = "1988",
month = "1",
day = "1",
doi = "10.1016/S0196-0644(88)80063-5",
language = "English (US)",
volume = "17",
pages = "1168--1175",
journal = "Annals of Emergency Medicine",
issn = "0196-0644",
publisher = "Mosby Inc.",
number = "11",

}

TY - JOUR

T1 - Emergency thrombolysis in acute myocardial infarction

AU - Heras, Magda

AU - Chesebro, James H.

AU - Gersh, Bernard G.

AU - Holmes, David

AU - Mock, Michael B.

AU - Fuster, Valentin

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The goal of thrombolytic treatment in acute myocardial infarction is to reestablish permanent blood flow, salvage ischemic myocardium, and reduce mortality. If patency is achieved sufficiently early and is maintained, left ventricular function is preserved and mortality decreases. The recent experience with tissue plasminogen activator and streptokinase in the TIMI I trial is reviewed with specific attention to reperfusion, reocclusion, and bleeding. Other studies concerning left ventricular preservation and mortality are also discussed. Current guidelines for antithrombotic therapy and thrombolysis are discussed. It is extremely important to adequately select patients to avoid side effects. Thorough lysis of the thrombus must be achieved to reduce the risk of rethrombosis. Simultaneous heparin should be administered to treat ongoing thrombosis. Additional antithrombotic therapy with aspirin and acute vasodilation to reduce vasoconstriction probably also decrease the likelihood of reocclusion. Because this treatment predisposes to bleeding, extreme care should be taken to avoid vascular punctures and invasive procedures in these patients. The association of immediate percutaneous transluminal coronary angioplasty has not been beneficial in preventing further events; on the contrary, adverse effects have been associated with this acute intervention.

AB - The goal of thrombolytic treatment in acute myocardial infarction is to reestablish permanent blood flow, salvage ischemic myocardium, and reduce mortality. If patency is achieved sufficiently early and is maintained, left ventricular function is preserved and mortality decreases. The recent experience with tissue plasminogen activator and streptokinase in the TIMI I trial is reviewed with specific attention to reperfusion, reocclusion, and bleeding. Other studies concerning left ventricular preservation and mortality are also discussed. Current guidelines for antithrombotic therapy and thrombolysis are discussed. It is extremely important to adequately select patients to avoid side effects. Thorough lysis of the thrombus must be achieved to reduce the risk of rethrombosis. Simultaneous heparin should be administered to treat ongoing thrombosis. Additional antithrombotic therapy with aspirin and acute vasodilation to reduce vasoconstriction probably also decrease the likelihood of reocclusion. Because this treatment predisposes to bleeding, extreme care should be taken to avoid vascular punctures and invasive procedures in these patients. The association of immediate percutaneous transluminal coronary angioplasty has not been beneficial in preventing further events; on the contrary, adverse effects have been associated with this acute intervention.

KW - myocardial infarction

KW - thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=0024158503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024158503&partnerID=8YFLogxK

U2 - 10.1016/S0196-0644(88)80063-5

DO - 10.1016/S0196-0644(88)80063-5

M3 - Article

C2 - 3056130

AN - SCOPUS:0024158503

VL - 17

SP - 1168

EP - 1175

JO - Annals of Emergency Medicine

JF - Annals of Emergency Medicine

SN - 0196-0644

IS - 11

ER -